3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
7
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Breast
1
Conditions
Breast Neoplasms
279
Triple Negative Breast Neoplasms
146
Neoplasm Metastasis
27
Ovarian Neoplasms
23
Carcinoma, Non-Small-Cell Lung
17
Inflammatory Breast Neoplasms
15
Pancreatic Neoplasms
12
Neoplasms
11
Endometrial Neoplasms
11
Breast Neoplasms, Male
11
Colorectal Neoplasms
8
Carcinoma, Ductal, Breast
8
Stomach Neoplasms
7
Parkinson Disease 4, Autosomal Dominant Lewy Body
7
Lung Neoplasms
7
Prostatic Neoplasms
6
Melanoma
6
Fallopian Tube Neoplasms
6
Uterine Cervical Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Sarcoma
5
Pathologic Complete Response
5
HER2-positive Breast Cancer
5
Carcinoma, Ovarian Epithelial
5
Esophageal Neoplasms
4
Carcinoma, Lobular
4
Urinary Bladder Neoplasms
3
Small Cell Lung Carcinoma
3
Recurrence
3
Multiple Myeloma
3
Interventions
pembrolizumab
2
Trastuzumab
2
Magnetic Resonance Spectroscopy
2
Immunoglobulin G
2
Fulvestrant
2
ulixertinib
1
tucatinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
seribantumab
1
sapanisertib
1
relatlimab
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
larotrectinib
1
ipatasertib
1
erdafitinib
1
durvalumab
1
defactinib
1
dabrafenib
1
copanlisib
1
cemiplimab
1
capivasertib
1
binimetinib
1
adavosertib
1
X-Rays
1
Sunitinib
1
Specimen Handling
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Neoplasms
×
Carboplatin
×
Breast
×
Clear all
NCT05579366
2026-06-03
RAINFOL-01
Genmab
Phase 1/2
Recruiting
884 enrolled